Brief: Unicycive Reports Key Findings Of Uni-494 Efficacy In Preclinical Animal Model Of Acute Kidney Injury (Aki)

Unicycive Therapeutics

07/09/2022 12:09

Sept 7 (Reuters) - Unicycive Therapeutics Inc  UNCY.O :
    * UNICYCIVE REPORTS KEY FINDINGS OF UNI-494 EFFICACY IN
PRECLINICAL ANIMAL MODEL OF ACUTE KIDNEY INJURY (AKI)
    * UNICYCIVE THERAPEUTICS INC - ON TRACK TO FILE REGULATORY
SUBMISSION BY YEAR END 2022 TO INITIATE FIRST-IN-HUMANS PHASE 1
STUDY WITH UNI-494
    * UNICYCIVE THERAPEUTICS INC - ESTABLISHED ANIMAL MODEL OF
AKI
SHOWED A STATISTICALLY SIGNIFICANT REDUCTION OF A KEY BIOMARKER
OF KIDNEY INJURY WHEN TREATED WITH UNI-494

Source text for Eikon:  ID:nGNX9B3jRg 
Further company coverage:  UNCY.O 

 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))